Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

PRED neuroscience development programs -1 Molecule Indication Phase # of patients Status Neuroscience Brain Shuttle-gantenerumab (BS- gantenerumab, RG6102) Alzheimer's disease lla Brain Shuttle-CD20 (BS-CD20, RG6035) Multiple sclerosis || = ralmitaront (partial TAAR1 agonist, RG7906) Schizophrenia || prasinezumab¹ || = (anti-aSynuclein, RG7935, PRX002) Parkinson's disease llb 19 Roche CT Identifier ~120 FPI Q1 2021 30 36 247 316 FPI Q3 2021 FPI Q4 2018; Recruitment completed Q3 2019 FPI Q4 2019 The study did not meet its primary endpoint, but showed a reduced clinical decline of core motor signs (MDS UPDRS partIII). Data presented at MDS & ADPD 2020-22. The Open Label Extension is ongoing. NCT04639050 ISRCTN16295 177 NCT03669640 (TWAIN I) NCT03100149 (PASADENA) 575 FPI Q2 2021 alogabat (GABA-Aa5 PAM, RG7816) NME (RG7637) rugonersen Autism spectrum disorder || 105 FPI Q1 2021 Neurodevelopmental disorders 80 FPI Q3 2020 Angelman syndrome 66 FPI Q3 2020 (UBE3A LNA, RG6091) NME (RG6182) Neurodegenerative disorder 50 30 FPI Q4 2020 Partner: 1Prothena BS Brain Shuttle NCT04777331 (PADOVA) NCT04299464 (Aurora) NCT04475848 NCT04428281 152
View entire presentation